Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Investigation of the Safety, Tolerability and Preliminary Antitumor Activity of BPT567, a Multifunctional PD1-IL18 Immunocytokine in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1 Investigation of the Safety, Tolerability and Preliminary Antitumor Activity of BPT567, a Multifunctional PD1-IL18 Immunocytokine in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BPT 567 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms SUMMIT-1
  • Sponsors Bright Peak Therapeutics

Most Recent Events

  • 17 Oct 2024 According to a Bright Peak Therapeutics media release, status changed from planning to recruiting.
  • 17 Oct 2024 According to a Bright Peak Therapeutics media release, the company announced that the first patient was dosed in its Phase 1/2a trial evaluating BPT567, an investigational bifunctional PD1-IL18 immunoconjugate and the study is expected to enroll approximately 100 patients.
  • 13 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top